Researchers also found that fisetin in combination with geldanamycin or radicicol in vivo study in human COLO205 colon cancer cells significantly increased expressions of caspase‐3 and caspase‐9 activities, modified the Bcl‐2 but not Bax protein or Bcl‐XL, and decreased the p53 protein along with enhancement in ubiquitin‐tagged proteins, respectively (Wu, Lien, Shen, Yang, & Chen, 2013; Yu, Yang, Peng, Yu, & Chiu, 2011). The gene discussed is BCL2; the disease is malignant colon neoplasm.